The tyrosine kinase inhibitor nintedanib activates SHP-1 and induces apoptosis in triple-negative breast cancer cells

Triple-negative breast cancer (TNBC) remains difficult to treat and urgently needs new therapeutic options. Nintedanib, a multikinase inhibitor, has exhibited efficacy in early clinical trials for HER2-negative breast cancer. In this study, we examined a new molecular mechanism of nintedanib in TNBC...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Exp Mol Med
Glavni autori: Liu, Chun-Yu, Huang, Tzu-Ting, Chu, Pei-Yi, Huang, Chun-Teng, Lee, Chia-Han, Wang, Wan-Lun, Lau, Ka-Yi, Tsai, Wen-Chun, Chao, Tzu-I, Su, Jung-Chen, Chen, Ming-Huang, Shiau, Chung-Wai, Tseng, Ling-Ming, Chen, Kuen-Feng
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 2017
Teme:
Original Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5579508/
https://ncbi.nlm.nih.gov/pubmed/28798401
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/emm.2017.114
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items